Johannes Kersting

Johannes Kersting

Auto-generated profile, based on publicly available information

Johannes Kersting

Data Science in Systems Biology, TUM School of Life Sciences, Technical University of Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in NAR Genomics and Bioinformatics
Verified
Journal Article
Open access
PDF file
AFAmit Fenn
Amit Fenn
OTOlga Tsoy
Olga Tsoy
TFTim Faro
Tim Faro
FRFanny L M Rößler
Fanny L M Rößler
ADAlexander Dietrich
Alexander Dietrich
MLMarkus List
Markus List
Alternative splicing is a major contributor to transcriptome and proteome diversity in health and disease. A plethora of tools have been developed for studying alternative splicing in RNA-seq data. Previous benchmarks focused on isoform quantification and mapping. They neglected event detection tools, which arguably provide the most detailed insights into the alternative splicing process. DICAST offers a modular and extensible framework for analysing alternative splicing integrating eleven splice-aware mapping and eight event detection tools. We benchmark all tools extensively on simulated as well as whole blood RNA-seq data. STAR and HISAT2 demonstrated the best balance between performance and run time. The performance of event detection tools varies widely with no tool outperforming all others. DICAST allows researchers to employ a consensus approach to consider the most successful tools jointly for robust event detection. Furthermore, we propose the first reporting standard to unify existing formats and to guide future tool development.

1 January 2023
Verified
Conference Paper
Open access
JKJohannes Kersting
Johannes Kersting
OLOlga Lazareva
Olga Lazareva
ZLzakaria louadi
zakaria louadi
Jan BaumbachJan Baumbach
Jan Baumbach
DBDavid B. Blumenthal
David B. Blumenthal
MLMarkus List
Markus List
Gene regulation is frequently altered in diseases in unique and often patient-specific ways. Hence, personalized strategies have been proposed to infer patient-specific gene-regulatory networks. However, existing methods do not focus on disease-specific dysregulation or lack assessment of statistical significance. Moreover, they do not account for clinically important confounding factors such as age, sex, or treatment history. To overcome these shortcomings, we present DysRegNet, a novel method for inferring patient-specific regulatory alterations (dysregulations) from gene expression profiles. We compared DysRegNet to SSN, the original sample-specific network approach, and demonstrated that DysRegNet produces more interpretable and biologically meaningful networks. We apply DysRegNet to eleven TCGA cancer types and illustrate how the inferred networks can be used for downstream analysis. We show that unique as well as cancer-type-specific dysregulation patterns exist and highlight immune-related mechanisms that are not obvious when focusing on individual genes rather than their interactions.

1 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JKJohannes Kersting
Johannes Kersting
OLOlga Lazareva
Olga Lazareva
ZLzakaria louadi
zakaria louadi
Jan BaumbachJan Baumbach
Jan Baumbach
DBDavid B. Blumenthal
David B. Blumenthal
MLMarkus List
Markus List
Gene regulation is frequently altered in diseases in unique and patient-specific ways. Hence, personalized strategies have been proposed to infer patient-specific gene-regulatory networks. However, existing methods do not scale well as they often require recomputing the entire network per sample. Moreover, they do not account for clinically important confounding factors such as age, sex, or treatment history. Finally, a user-friendly implementation for the analysis and interpretation of such net-works is missing. We present DysRegNet, a method for inferring patient-specific regulatory alterations (dysregulations) from bulk gene expression profiles. We compared DysRegNet to SSN, a well-known sample-specific network approach. We demonstrate that both SSN and DysRegNet produce interpretable and biologically meaningful networks across various cancer types. In contrast to SSN, DysRegNet can scale to arbitrary sample numbers and highlights the importance of confounders in network inference, revealing an age-specific bias in gene regulation in breast cancer. DysRegNet is available as a Python package ( https://github.com/biomedbigdata/DysRegNet_package ), and analysis results for eleven TCGA cancer types are available through an interactive web interface ( https://exbio.wzw.tum.de/dysregnet ).

12 September 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Christian GrätzChristian Grätz
Christian Grätz
PCPrashant Changoer
Prashant Changoer
DCDapi Menglin Chiang
Dapi Menglin Chiang
JKJohannes Kersting
Johannes Kersting
MJmartin Jaeger
martin Jaeger
Michael W. PfafflMichael W. Pfaffl
Michael W. Pfaffl
Anaplastic thyroid cancer (ATC) is an aggressive and rare disease. Rapid metastasis and limited treatments call for additional therapeutic options, including drug repurposing. The early spreading of ATC highlights the importance of rapid therapy success assessment, which could be achieved by measurement of extracellular vesicle (EV)-associated cell-free RNA in liquid biopsy samples. Recent studies have discovered the potential of the receptor tyrosine kinase inhibitor vandetanib for ATC treatment in vitro and in vivo. Given the rarity of ATC patients receiving off-label vandetanib treatment, acquiring patient samples for clinical studies is a prolonged process, and pre-clinical investigations are needed to elucidate the effects of vandetanib on ATC cells. Here, we present an in vitro study addressing holistic transcriptional and proteomic changes induced in the ATC cell line Cal62 by three doses of vandetanib and quantified by high-throughput methods. By comparing the transcriptional and proteomic data sets and applying dimensional reduction models such as sparse partial least-squares discriminant analysis, we refined a set of 21 biomarker candidates. Out of these, we report a final signature of eight transcriptional biomarkers, validated in cellular and cell-free RNA by RT-qPCR and verified for biological significance and discriminatory power by pathway over-representation analysis and partial least-squares regression. This transcriptional biomarker signature can distinguish vandetanib treatment from control in cell-free RNA isolated from Cal62 EVs and can be measured reliably, easily, and quickly using RT-qPCR. Our findings may serve as a basis for future clinical trials with liquid biopsy samples from ATC patients undergoing off-label vandetanib treatment.

4 December 2024 in British Journal of Pharmacology
Verified
Journal Article
Open access
JKJohannes Kersting
Johannes Kersting
OLOlga Lazareva
Olga Lazareva
ZLzakaria louadi
zakaria louadi
Jan BaumbachJan Baumbach
Jan Baumbach
DBDavid B. Blumenthal
David B. Blumenthal
MLMarkus List
Markus List
Background and Purpose: Gene regulation is frequently altered in diseases in unique and patient‐specific ways. Hence, personalised strategies have been proposed to infer patient‐specific gene‐regulatory networks. However, existing methods do not scale well because they often require recomputing the entire network per sample. Moreover, they do not account for clinically important confounding factors such as age, sex or treatment history. Finally, a user‐friendly implementation for the analysis and interpretation of such networks is missing. Experimental Approach: We present DysRegNet, a method for inferring patient‐specific regulatory alterations (dysregulations) from bulk gene expression profiles. We compared DysRegNet to the well‐known SSN method, considering patient clustering, promoter methylation, mutations and cancer‐stage data. Key Results: We demonstrate that both SSN and DysRegNet produce interpretable and biologically meaningful networks across various cancer types. In contrast to SSN, DysRegNet can scale to arbitrary sample numbers and highlights the importance of confounders in network inference, revealing an age‐specific bias in gene regulation in breast cancer. DysRegNet is available as a Python package ( https://github.com/biomedbigdata/DysRegNet_package ), and analysis results for 11 TCGA cancer types are available through an interactive web interface ( https://exbio.wzw.tum.de/dysregnet ). Conclusion and Implications: DysRegNet introduces a novel bioinformatics tool enabling confounder‐aware and patient‐specific network analysis to unravel regulatory alteration in complex diseases. LINKED ARTICLES: This article is part of a themed issue Network Medicine and Systems Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.8/issuetoc

27 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EUElisabeth Urbauer
Elisabeth Urbauer
DADoriane Aguanno
Doriane Aguanno
NMNora Mindermann
Nora Mindermann
HOHélène Omer
Hélène Omer
AMAmira Metwaly
Amira Metwaly
SJSebastian Jarosch
Sebastian Jarosch
Summary: Mitochondrial dysfunction is associated with inflammatory bowel diseases (IBD). To understand how microbial-metabolic circuits contribute to intestinal tissue injury, we disrupt mitochondrial function in the epithelium by deleting heat shock protein 60 (Hsp60 Δ/ΔIEC ). While metabolic perturbation causes self-resolving tissue injury, regeneration is disrupted in the absence of aryl hydrocarbon receptor (Hsp60 Δ/ΔIEC ;AhR -/- ) or IL-10 (Hsp60 Δ/ΔIEC ;Il10 -/- ) leading to IBD-like pathology. Injury is absent in the distal colon of germ-free (GF) Hsp60 Δ/ΔIEC mice, highlighting bacterial control of metabolic injury. Selective colonization of GF Hsp60 Δ/ΔIEC mice with the synthetic community OMM 12 confirms consistent expansion of metabolically-flexible Bacteroides spp. across all models and mono-colonization with B. caecimuris recapitulates injury. Transcriptional profiling of metabolically-impaired epithelium identifies gene signatures, including Ido1 , Nos2 , and Duox2 , distinguishing active from inactive tissue inflammation in 343 resected samples from Crohn’s disease patients. In conclusion, mitochondrial perturbation of the epithelium causes microbiota-dependent tissue injury and discriminative inflammatory gene profiles relevant for IBD. Abstract Figure: Graphical Control of metabolic injury by microbial signals.: Mitochondrial perturbation of the intestinal epithelium induces tissue injury Loss of IL-10 and AhR-related host mechanisms accelerate injury and inflammation Mitochondrial dysfunction induces dysbiosis and expansion of Bacteroides spp. Metabolic injury gene signature discriminates inflamed vs. non-inflamed IBD samples